Michael Cherny, an analyst from Leerink Partners, maintained the Hold rating on Quest Diagnostics (DGX – Research Report). The associated price target is $169.00. Don't Miss our Black Friday Offers: ...

Quest Diagnostics DGX is set to release its second-quarter 2025 results on July 22, before the market opens. The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.21 in the ...

LONDON, UNITED KINGDOM, October 4, 2024 /EINPresswire.com/ -- Aspire Performance Improvement Limited is thrilled to announce the release of its cutting-edge ...

On Tuesday, Quest Diagnostics Inc (NYSE:DGX) posted second-quarter adjusted EPS of $2.35, beating the consensus of $2.34. Sales increased 2.5% year-over-year to $2.39 billion, almost in line with the ...

SALT LAKE CITY, April 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced ...

Diversified science and technology company Danaher (NYSE:DHR) in Q4 CY2025, with sales up 4.6% year on year to $6.84 billion. Its non-GAAP profit of $2.23 per share was 1.8% above analysts’ consensus ...

Performance bottlenecks have the potential to effectively cripple an entire organization, which can spell disaster for the enterprise. The lengthy downtime caused by poor database performance ...

Assessing the skills of junior female footballers in realistic game situations: this is now possible with the new SCoRE performance diagnostics system developed by the University of Würzburg. The ...